A patient diagnosed with cancer today is not a death sentence
Across Latin America, a 70 percent rise in cancer cases is projected by 2045—not as an inevitability written in biology alone, but as a convergence of modifiable habits, uneven health systems, and the slow arrival of transformative medicine. The region stands at a threshold where the choices made today about prevention, screening, and access will determine whether this surge becomes a manageable burden or an overwhelming one. What science can now offer—precision therapies, immunotherapy, targeted treatments—has genuinely changed what a cancer diagnosis means, but only for those who can reach it.
- A 70% increase in cancer cases by 2045 is bearing down on Latin American health systems already stretched thin, with breast, prostate, colorectal, lung, and stomach cancers leading the wave.
- Gastrointestinal cancers dominate mortality tallies across the region, exposing deep gaps in early diagnosis and treatment access that statistics alone cannot fully convey.
- Much of the projected surge is preventable—smoking, alcohol, obesity, and infections like HPV and hepatitis are modifiable risks that public health intervention can meaningfully reduce.
- Precision medicine and immunotherapy have transformed advanced cancer from a death sentence into, in many cases, a manageable chronic condition—but these tools remain out of reach for much of the region's population.
- The critical battleground is access: screening programs are inconsistent, innovative treatments are unevenly distributed, and the infrastructure for precision oncology is still being constructed across the region.
Para 2045, México y América Latina enfrentarán una carga de casos de cáncer un 70 por ciento mayor que la actual. Francisco Olguín, director médico de oncología de Pfizer México, presentó este panorama en un foro periodístico sobre la enfermedad: los cánceres más frecuentes en la región son los de mama, próstata, colorrectal, pulmón y estómago, mientras que los tumores gastrointestinales encabezan las cifras de mortalidad. En México, el cáncer de mama lidera en frecuencia, pero el colorrectal ocupa el primer lugar en muertes.
El mensaje central de Olguín no fue de resignación, sino de responsabilidad. Gran parte de este aumento es prevenible: el tabaco, el alcohol, la obesidad y ciertas infecciones como el VPH, la hepatitis B y C, y el Helicobacter pylori elevan el riesgo de manera significativa, y todos son susceptibles de intervención. La vacunación contra estos patógenos, subrayó, no solo protege en el momento, sino que puede prevenir ciertos cánceres décadas después.
La detección temprana sigue siendo el escudo más confiable, pero la medicina de precisión ha redibujado el horizonte del tratamiento. Hoy es posible identificar las mutaciones moleculares específicas de cada tumor y diseñar terapias a su medida. La inmunoterapia y los anticuerpos biespecíficos representan una nueva generación de herramientas que atacan las células cancerosas con una precisión sin precedentes. Un diagnóstico que hace una década equivalía a una sentencia de muerte es hoy, en muchos casos, una condición crónica tratable.
Sin embargo, la brecha entre lo posible y lo accesible sigue siendo enorme. El aumento proyectado llegará a una región con programas de detección irregulares y tratamientos innovadores fuera del alcance de quienes carecen de recursos. La prevención, la detección oportuna y el acceso a estas terapias no son lujos: son la diferencia entre un futuro manejable y uno catastrófico.
By 2045, Mexico and Latin America will confront a wave of cancer cases 70 percent larger than today—a projection that cuts through the usual health statistics to pose a concrete question: what happens when a region's medical systems are already strained, and the patient load is about to explode?
Francisco Olguín, medical director of oncology for Pfizer Mexico, laid out the landscape at a journalism forum on cancer. The cancers most likely to strike across Mexico, Colombia, Costa Rica, and the Dominican Republic are breast, prostate, colorectal, lung, and stomach tumors. But the killers—the ones that show up most often in mortality tallies—are gastrointestinal cancers, breast cancer, and prostate cancer. In Mexico specifically, breast cancer leads the frequency count, followed by prostate, colorectal, and lung. When it comes to deaths, colorectal cancer ranks first, then breast, lung, liver, prostate, and stomach.
The arithmetic is grim, but Olguín's point was not despair. It was that much of this surge is preventable. Yes, some risk factors sit beyond anyone's control—age, family history, inherited genetic mutations. But others do not. Smoking, alcohol consumption, obesity, and certain infections all push cancer risk upward, and all are within reach of intervention. Tobacco does not just cause lung cancer; it also drives cancers of the mouth, larynx, head, neck, and bladder. Alcohol correlates with gastrointestinal cancers and breast cancer. Infections like human papillomavirus, hepatitis B and C, and Helicobacter pylori can tip the scales toward malignancy. Vaccination against these pathogens, Olguín emphasized, does more than prevent infection in the moment—it can prevent certain cancers decades down the line.
Early detection remains the most reliable shield. Screening tests, when available and used, catch disease in its earlier stages, when survival odds are far better. But Olguín also pointed to a second front: the revolution in how cancer is treated. Precision medicine has redrawn the map. Instead of one-size-fits-all chemotherapy, doctors now identify the specific molecular mutations in each tumor and select treatments tailored to those mutations. Immunotherapy harnesses the patient's own immune system. Targeted therapies and bispecific antibodies represent a new generation of weapons that strike cancer cells with far greater accuracy than older approaches.
The shift is not merely academic. These innovations have changed the trajectory of multiple cancer types, opening treatment doors for patients who once faced dead ends. A diagnosis that would have been a death sentence a decade ago is now, in many cases, a chronic condition to be managed. "A patient diagnosed with cancer today is not receiving a death sentence," Olguín said. "These advances in diagnostic and treatment technology are helping to modify the disease so that patients not only live longer but live better."
Yet the gap between what is possible and what is accessible remains vast. The 70 percent surge in cases will arrive in a region where screening programs are patchy, where innovative treatments are often out of reach for those without resources, and where the infrastructure to deliver precision medicine is still being built. Prevention, early detection, and access to these new treatments are not luxuries—they are the difference between a manageable future and a catastrophic one.
Notable Quotes
A patient diagnosed with cancer today is not receiving a death sentence. These advances in diagnostic and treatment technology are helping to modify the disease so that patients not only live longer but live better.— Francisco Olguín, medical director of oncology for Pfizer Mexico
The importance of vaccination is not only to prevent infection, but in the long term it can also help prevent some cancers.— Francisco Olguín
The Hearth Conversation Another angle on the story
Why does a 70 percent increase matter so much? Aren't cancer rates always rising?
The scale is what matters. This isn't a slow creep—it's a surge that will overwhelm systems already struggling to handle current demand. And it's not inevitable. Much of it is driven by modifiable factors.
Like what, specifically?
Smoking, alcohol, obesity, infections we can now vaccinate against. These aren't genetic destiny. They're choices and conditions that can be changed, but only if people have the information and access to prevention.
So prevention is the answer?
It's part of it. But prevention only works if it reaches people before they get sick. For those who do get cancer, early detection is the next line. Catch it at stage one instead of stage four, and survival odds transform.
And if it's already advanced?
That's where precision medicine comes in. Ten years ago, advanced cancer meant limited options. Now doctors can map the tumor's mutations and choose treatments designed for that specific cancer. It's not a cure-all, but it's changed what's possible.
But these treatments—they're expensive, aren't they?
Very. And that's the real crisis hiding in these numbers. The surge is coming to a region where most people don't have access to screening, let alone precision medicine. The gap between what medicine can do and what people can actually get is about to widen dramatically.